Ledipasvir
- Generic Name
- Ledipasvir
- Brand Names
- Harvoni
- Drug Type
- Small Molecule
- Chemical Formula
- C49H54F2N8O6
- CAS Number
- 1256388-51-8
- Unique Ingredient Identifier
- 013TE6E4WV
- Background
Ledipasvir is a direct acting antiviral (DAA) medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in the United States, and affecting ...
- Indication
When used in combination with the antiviral medication sofosbuvir, ledipasvir is indicated for the treatment of treatment of chronic hepatitis C virus (HCV) in adults and pediatric patients 3 years of age and older with the following conditions:
Its use has also proven successful in the treatment of HCV in patients co-infected with HIV .
- Associated Conditions
- Chronic Hepatitis C Genotype 1, Chronic hepatitis C genotype 5, Genotype 4 Chronic Hepatitis C, Genotype 6 chronic hepatitis C infection
- Associated Therapies
- -
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.